Biocon Gets USFDA Nod for Anti-Bacterial Drug
x
Biocon Pharma receives USFDA approval for Rifaximin Tablets, used to treat hepatic encephalopathy and irritable bowel syndrome.
New Delhi, Oct 7 (PTI) Biocon on Tuesday said its unit in partnership with Carnegie Pharmaceuticals LLC has received approval from the US health regulator for a genetic anti-bacterial medication.
Biocon Pharma, a wholly-owned subsidiary of the company, in partnership with Carnegie, has received tentative approval from the US Food and Drug Administration (USFDA) for the ANDA for Rifaximin Tablets, 550 mg, the company said in a regulatory filing.
Rifaximin tablets are indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhoea (IBS-D) in adults.
Shares of the company were trading flat at Rs 347 apiece on the BSE.
Biocon Pharma, a wholly-owned subsidiary of the company, in partnership with Carnegie, has received tentative approval from the US Food and Drug Administration (USFDA) for the ANDA for Rifaximin Tablets, 550 mg, the company said in a regulatory filing.
Rifaximin tablets are indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhoea (IBS-D) in adults.
Shares of the company were trading flat at Rs 347 apiece on the BSE.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Sylph-Industries
- 0.93 (+ 3.33)
- 61373733
- Vodafone-Idea
- 9.26 ( -3.34)
- 34841801
- Pulsar-Intl
- 0.90 (+ 4.65)
- 24588500
- Alstone-Textiles
- 0.14 ( 0.00)
- 24394567
- Spicejet
- 13.80 ( -6.25)
- 23735759
MORE NEWS
© 2026 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback